Some 60 years ago, a doctor in Baltimore removed cancer cells from a poor black patient named Henrietta Lacks without her knowledge or consent. Those cells eventually helped lead to a multitude of medical treatments and lay the groundwork for the multibillion-dollar biotech industry. Now, for the first time, the Lacks family has been given a say over at least some research involving her cells.
Stem cell therapy is in its infancy, but has the potential to change the way we treat cancer and other diseases by replacing damaged or diseased cells with healthy ones. Identifying the right cells to use is the challenge, and scientists in the U.K. have found a way to use gold nanoprobes with surface enhanced Raman spectroscopy to differentiate the nearly identical cells.
Reaching a clinic in time to receive an early diagnosis for cancer—when the disease is most treatable—is a global problem. And now a team of Chinese researchers proposes a global solution: have a user-friendly diagnostic device travel to the patient, anywhere in the world.
A research team at the National Institute for Materials Science in Japan has developed a new nanofiber mesh which is capable of simultaneously performing thermotherapy and chemotherapy of tumors. Using this new mesh, the team succeeded in efficiently inducing natural death of epithelial cancer cells.
Evidence is mounting that the development and spread of cancer, long attributed to gene expression and chemical signaling gone awry, involves a biomechanical component as well. Researchers at Lawrence Berkeley National Laboratory have added to this body of evidence by demonstrating that the malignant activity of a critical cellular protein system can arise from what essentially are protein traffic jams.
Scientists at the University of California, San Diego have designed tiny spherical particles to float easily through the bloodstream after injection, then assemble into a durable scaffold within diseased tissue. An enzyme produced by a specific type of tumor can trigger the transformation of the spheres into net-like structures that accumulate at the site of a cancer.
Scientists in Missouri have successfully created nanoparticles made of a radioactive form of the element lutetium. By covering these particles with gold shells and attaching targeting agents, they have a tool that can seek out dangerous secondary lymphoma tumors. They recently demonstrated the nanoparticles can find the tumors without attaching to or damaging healthy cells.
The University of Chicago has recently launched the first secure cloud-based computing system that enables researchers to access and analyze human genomic cancer information, such as the The Cancer Genome Atlas, without the costly and cumbersome infrastructure normally needed to download and store massive amounts of data.
Aerospace conglomerate United Technologies Corp. says it's donated $3 million to establish an endowed professorship at the Yale Cancer Center in New Haven. Lieping Chen will be the first United Technologies Corp. Professor in Cancer Research and is known for research leading to clinical trials of new cancer drugs that harness the body's immune system to fight cancer.
When cells suffer too much DNA damage, they are usually forced to undergo programmed cell death, or apoptosis. However, cancer cells often ignore these signals, flourishing even after chemotherapy drugs have ravaged their DNA. A new finding may offer a way to overcome that resistance: A team has identified a key protein involved in an alternative death pathway known as programmed necrosis.
Cancer patients could face high costs for medications under President Barack Obama's health care law, industry analysts and advocates warn. Where you live could make a huge difference in what you'll pay. To try to keep premiums low, some states are allowing insurers to charge patients a hefty share of the cost for expensive medications used to treat cancer, multiple sclerosis, rheumatoid arthritis, and other life-altering chronic diseases.
Eli Lilly and Co. said Friday it will stop development of an experimental cancer drug after it failed in a late-stage clinical trial. The company was studying enzastaurin as a treatment for diffuse large B-cell lymphoma, a cancer that affects a type of white blood cell. Lilly said patients who were treated with enzastaurin did not survive longer than patients treated with a placebo.
Like picking a career or a movie, cells have to make decisions—and cancer results from cells making wrong decisions. At the cellular level, wrong decisions can be made right. A team has discovered that colon cancer stem cells, a particularly malignant population of cancer cells, are able to switch between the decision to proliferate or to remain constant—and this “switch” is controlled by a little-studied molecule called microRNA.
Researchers at Washington University in St. Louis, using powerful algorithms developed by computer scientists at Brown University, have assembled the most complete genetic profile yet of acute myeloid leukemia, an aggressive form of blood cancer.
Cancer cells are wily, well-traveled adversaries, constantly side-stepping treatments to stop their spread. But, for the first time, scientists at the University of Michigan have decoded the molecular chatter that ramps certain cancer cells into overdrive and can cause tumors to metastasize throughout the body.
Researchers at the University of Illinois have identified biomarkers that can be used to determine ovarian cancer survival and recurrence, and have shown how these biomarkers interact with each other to affect these outcomes. The team used data from the Cancer Genome Atlas, which contains information about ovarian cancer patients’ age, survival, cancer recurrence, treatment, tumor stage, tumor grade, and genomic expression.
To get a better understanding of metastasis, more than 95 graduate students, post docs and professors in a variety of laboratories across the U.S. subjected two cell lines to a battery of tests and measurements using more than 20 different techniques. The work has enabled a comprehensive cataloging and comparison of the physical characteristics of non-malignant and metastatic cells.
Cancer cells that can break out of a tumor and invade other organs are more aggressive and nimble than nonmalignant cells, according to a new multi-institutional nationwide study. These cells exert greater force on their environment and can more easily maneuver small spaces.
Doctors have begun to categorize breast cancers into four main groups according to the genetic makeup of the cancer cells. Which category a cancer falls into generally determines the best method of treatment. But cancers in one of the four groups—called "basal-like" or "triple-negative" breast cancer (TNBC)—have been particularly tricky to treat. Researchers have developed a potential treatment for TNBC that uses nanodiamonds.
Nitric oxide (NO), a gas with many biological functions in healthy cells, can also help some cancer cells survive chemotherapy. A new study from Massachusetts Institute of Technology (MIT) reveals one way in which this resistance may arise, and raises the possibility of weakening cancer cells by cutting off their supply of NO.
Cancer painfully ends more than 500,000 lives in the United States each year, according to the Centers for Disease Control and Prevention. The scientific crusade against cancer recently achieved a victory under the leadership of University of Missouri Curators’ Professor M. Frederick Hawthorne. Hawthorne’s team has developed a new form of radiation therapy that successfully put cancer into remission in mice. This innovative treatment produced none of the harmful side-effects of conventional chemo and radiation cancer therapies.
A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person's risk for breast, ovarian or prostate cancer, scientists reported Wednesday. The potential payoff for ordinary people is mostly this: Someday there may be genetic tests that help identify women with the most to gain from mammograms, and men who could benefit most from PSA tests and prostate biopsies.
A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person's risk for breast, ovarian, or prostate cancer, scientists reported Wednesday.
Researchers from Georgia Tech and Children's Healthcare of Atlanta have developed a technique that assists in identifying tumors from normal brain tissue during surgery by staining tumor cells blue. The technique could be critically important for hospitals lacking sophisticated equipment in preserving the maximum amount of normal tissue and brain function during surgery.
Most people who are killed by cancer are victims of the spread of the original cancerous tumor, which is why researchers vigorously search for drugs that can prevent metastases. In a finding that could help accelerate that effort, researchers have found a chemical compound that appears to control cell migration and adhesion, two important characteristics of metastatic cancer cells.